| Literature DB >> 35204602 |
Valentina Scano1, Alessandro Giuseppe Fois1,2, Andrea Manca1, Francesca Balata1, Angelo Zinellu3, Carla Chessa4, Pietro Pirina1,2, Panos Paliogiannis1.
Abstract
Mediastinal lymphadenopathy is a condition in which one or more mediastinal lymph nodes are enlarged for malignant or benign causes, generally more than 10 mm. For a long time, the only way to approach the mediastinum was surgery, while in last decades endoscopic techniques gained their role in neoplastic diseases. At the present time, EBUS is the technique of choice for studying the mediastinum in the suspicion of cancer, while there are not strong indications in guidelines for the study of benign mediastinal lymphadenopathy. We reviewed the literature, looking for evidence of the role of EBUS in the diagnostics of non-neoplastic mediastinal lymphadenopathy, with special regard for granulomatous disease, both infectious and non-infectious. EBUS is a reliable alternative to surgery in non-neoplastic mediastinal lymphadenopathy, even if more evidence is needed for granulomatous diseases other than tuberculosis and sarcoidosis.Entities:
Keywords: EBUS-TBNA; granulomatous diseases; mediastinal lymphadenopathy
Year: 2022 PMID: 35204602 PMCID: PMC8871250 DOI: 10.3390/diagnostics12020512
Source DB: PubMed Journal: Diagnostics (Basel) ISSN: 2075-4418
Figure 1IASLC mediastinal lymph node map, courtesy of El-Sherief et al. [11].
Figure 2Cytological sample showing loosely aggregated epithelioid cells without necrosis, stained in Diff Quick for rapid on-site evaluation. Courtesy of von Bartheld et al. [37] who own the copyright.
Figure 3Role of EBUS and EUS in reaching mediastinal lymph nodes, as outlined by Paul Clementsen [2] who is the owner of the copyright.
Scheme of principal causes of mediastinal lymph node enlargement.
| Causes of Mediastinal Lymphadenopathy | |
|---|---|
| Malignant Causes | Benign Causes |
Resumptive table of diagnostic yield of EBUS-TBNA in sarcoidosis.
| Author | EBUS Diagnostic Yield | Population | Type of Study |
|---|---|---|---|
| Tremblay et al. 2009 | 83.3% | 50 | Randomized controlled trial |
| Nakajima et al. 2009 | 91.4% | 35 | Randomized controlled trial |
| Von Bartheld et al. 2010 | 92% for Scadding stage I, 77% for Scadding stage II | 101 | Descriptive study |
| Navani et al. 2011 | 85% (93% combined with TBB) | 39 | Descriptive study |
| von Bartheld et al. 2013 | 80% | 155 | Randomized controlled trial |
| Ortakoylu et al. 2015 | 83% | 159 | Descriptive study |
| Trisolini et al. 2015 | 79% | 2097 | Meta-analysis |
A resumptive table of diagnostic yield of EBUS for mycobacterial disease.
| Author | EBUS Diagnostic Yield | Population | Type of Study |
|---|---|---|---|
| Çağlayan et al. 2011 | 84.2% | 19 | Descriptive study |
| Sun et al. 2013 | 90% | 41 | Descriptive study |
| Low et al. 2014 | 70% | 18 | Descriptive study |